NewsBite

Botanix Pharmaceuticals Ltd

ASX Announcements

Market Sensitive

December 2024 Quarterly Activities Report and Appendix 4C

CTE – Second Quarter Cashflow Report, CTE - Second Quarter Activity Report

  • Jan 31, 2025
  • 10 pages

Change of Director's Interest Notice - V. Ippolito

Change of Director’s Interest Notice

  • Jan 17, 2025
  • 3 pages

Change in substantial holding from IFL

Change in substantial holding

  • Jan 15, 2025
  • 7 pages

Change of Director's Interest Notice - V. Ippolito

Change of Director’s Interest Notice

  • Jan 9, 2025
  • 2 pages

Application for quotation of securities - BOT

Appendix 2A (Application for Quotation of Securities)

  • Jan 9, 2025
  • 6 pages

View all BOT announcements

January

Lennox Capital’s Liam Donohue.

This media company’s share price is tipped to double

Lennox small caps manager Liam Donohue says he’s bullish on Botanix Pharmaceuticals and explains why he is eyeing up some former market darlings.

  • Joanne Tran

September 2024

.

The five pharma stocks exciting investors

Risky but with rewards, Australian pharmaceutical companies developing treatments for rare diseases are competing for investor attention.

  • Michael Smith

August 2022

Street Talk.

Botanix Pharmaceuticals raising for its sweating treatment

Botanix Pharmaceuticals, a listed developer of treatments for skin infections and diseases, was pitching investors for $5 million to take its Sofpironium Bromide product into sales in the United States. 

  • Anthony Macdonald, Sarah Thompson and Kanika Sood

Original URL: https://www.afr.com/company/bot-ah